NEW Warren-Hawley Bill Crushes Big Medicine

Two file folders labeled DRAFT and BILL stacked on a desk

Senators Elizabeth Warren and Josh Hawley, in a rare bipartisan move, introduce legislation to shatter “Big Medicine” conglomerates that drive up healthcare costs for working Americans—could this be the antitrust win President Trump’s agenda needs?

Story Highlights

Warren (D-MA) and Trump ally Hawley (R-MO) target UnitedHealthcare, CVS Health, and Cigna for owning insurers, PBMs, pharmacies, and providers simultaneously.
Bill prohibits “double-dipping” across healthcare supply chains, forcing divestitures within three years to slash drug prices and restore competition.
Builds on failed 2024 effort amid Trump-era PBM crackdowns, empowering FTC, HHS, and DOJ enforcement.
Addresses consolidation where seven healthcare giants dominate Fortune 20, controlling 80% of prescription claims and 75% of doctors.
Promised relief for families battered by Biden-era inflation in medical costs, aligning with conservative demands for affordability.

Bill Targets Vertical Monopolies in Healthcare

Senators Elizabeth Warren and Josh Hawley introduced bipartisan legislation on a Tuesday, exclusively reported by CBS News. The bill dismantles vertically integrated conglomerates like UnitedHealthcare’s Optum Rx and CVS Health’s Caremark and Aetna. These firms control insurers, pharmacy benefit managers (PBMs), pharmacies, and medical providers. The measure prohibits ownership on both sides of healthcare transactions. This aims to curb profiteering that inflates costs for everyday Americans. President Trump’s prior executive orders against PBM middlemen set the stage for this revival.

Historical Consolidation Fuels Crisis

Healthcare consolidation exploded after 2000, placing seven conglomerates in the Fortune 20 where none existed before. UnitedHealth Group emerged as the largest U.S. healthcare firm and top doctor employer. By 2022, 97% of metro areas faced highly concentrated hospital markets, with one or two systems controlling 82% of beds. Over 75% of doctors now work for hospitals, insurers, or private equity by 2023. PBMs like Optum Rx, Caremark, and Express Scripts process 80% of claims. Ownership by insurers enables steering to affiliates, kickbacks, and exclusion of independent pharmacies.

Bipartisan Push Echoes Trump Policies

The new bill expands the 2024 Patients Before Monopolies Act, which died in Congress despite sponsors including Reps. Diana Harshbarger (R-TN) and Jake Auchincloss (D-MA). Warren demands breaking up conglomerates to end their stranglehold on costs. Hawley blasts Big Pharma and insurers gobbling providers, insisting working Americans deserve better. Rep. Greg Murphy (R-NC) calls to shatter UnitedHealthcare into pieces. Recent Trump-signed appropriations included PBM rules. FTC’s settlement with Express Scripts fell short, urging congressional action. This aligns with Trump’s focus on affordability over corporate excess.

Industry defenders like CVS Health’s David Joyner claim vertical models serve consumers well. Yet doctors and nurses report post-acquisition crises, including staffing shortages linked to patient deaths. The American Economic Liberties Project highlights monopolies forcing inferior options and price hikes. In Trump’s America, where Biden’s fiscal mismanagement fueled inflation, this bipartisan effort promises real relief by restoring competition akin to Glass-Steagall for banking. Families strained by high drug and visit costs stand to gain most.

Potential Impacts on Costs and Care

Short-term, the bill mandates divestitures within three years, enabling lawsuits and penalties while boosting independent pharmacies and providers. Long-term, it eliminates double-dipping, lowers drug and visit prices, and revives competition. Consumers benefit from reduced costs amid ongoing inflation battles. Doctors and nurses anticipate better care without corporate interference denying claims via kickbacks. Conglomerates forfeit integration profits that prioritize shareholders over patients. Politically, it offers a midterm win on affordability, setting antitrust precedents. State bans on corporate doctor ownership gain momentum.